Clinical trial
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in…
NCT00077532 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00077532 |
|---|---|
| Title | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma |
| Official title | A Study of Intra-Patient Escalating Doses of MDX-010 Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 in the Treatment of Patients With Stage IV Melanoma |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | gp100 antigen, incomplete Freund's adjuvant, ipilimumab |
| Enrollment | 179 |
| Start date | Mar 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Feb 12, 2004 |
| Last update posted | Jun 22, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: